ARCOXIA TABLET 120 mg

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

即購入

製品の特徴 製品の特徴 (SPC)
05-06-2023

有効成分:

ETORICOXIB

から入手可能:

ORGANON SINGAPORE PTE. LTD.

ATCコード:

M01AH05

投薬量:

120 mg

医薬品形態:

TABLET, FILM COATED

構図:

ETORICOXIB 120 mg

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

Rovi Pharma Industrial Services S.A.

認証ステータス:

ACTIVE

承認日:

2002-10-18

情報リーフレット

                                 
 
SG-SPC-MK0663-T-082011 
 
Trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Whitehouse
Station, NJ,, 
USA 
Copyright © 2011 Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, 
NJ, USA 
 
All rights reserved Page 1 
 
1. 
NAME OF THE MEDICINAL PRODUCT 
 
ARCOXIA
®
 30 mg Film-coated Tablets  
ARCOXIA
®
 60 mg Film-coated Tablets  
ARCOXIA
®
 90 mg Film-coated Tablets  
ARCOXIA
®
 120 mg Film-coated Tablets  
 
 
2. 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Each film-coated tablet contains 30, 60, 90 or 120 mg of etoricoxib.  For excipients, see 
6.1. 
 
3. 
PHARMACEUTICAL FORM 
 
Film-coated tablet. 
 
30mg Tablets: Blue-green, apple-shaped, biconvex tablets debossed '101' on one side and 
'ACX 30' on the other side. 
 
60 mg  Tablets:    Dark  green,  apple-shaped,  biconvex  tablets  debossed  ‘200’  on  one  side 
and ‘ARCOXIA 60’ on the other side. 
 
90 mg  Tablets:    White,  apple-shaped,  biconvex  tablets  debossed  ‘202’  on  one  side  and 
‘ARCOXIA 90’ on the other side. 
 
120 mg Tablets:  Pale-green, apple-shaped, biconvex tablets debossed ‘204’ on one side 
and ‘ARCOXIA 120’ on the other side. 
 
 
4. 
CLINICAL PARTICULARS 
 
4.1 
THERAPEUTIC INDICATIONS 
 
ARCOXIA tablets are indicated for: 
- Symptomatic relief of osteoarthritis (OA),  
- Rheumatoid arthritis (RA), 
- Symptomatic relief of ankylosing spondylitis (AS), 
- Pain and signs of inflammation associated with
acute gouty arthritis, 
-  Treatment  of  acute  pain,  including  that  related  to  primary  dysmenorrhea  and  minor 
dental procedures. 
The decision to prescribe a selective COX-2 inhibitor should be based on an assessment 
of  the  individual  patient’s  overall  risks,  taking
                                
                                完全なドキュメントを読む
                                
                            

製品の特徴

                                SG-SPC-OG0663-T-012023
1.
NAME OF THE MEDICINAL PRODUCT
ARCOXIAⓇ 30 mg Film-coated Tablets
ARCOXIAⓇ 60 mg Film-coated Tablets
ARCOXIAⓇ 90 mg Film-coated Tablets
ARCOXIAⓇ 120 mg Film-coated Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 30, 60, 90 or 120 mg of etoricoxib.
For excipients, see
6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
30 mg Tablets: Blue-green, apple-shaped, biconvex tablets debossed
‘101’ on one side
and ‘ACX 30’ on the other side.
60 mg Tablets: Dark green, apple-shaped, biconvex tablets debossed
‘200’ on one side
and ‘ARCOXIA 60’ on the other side.
90 mg Tablets: White, apple-shaped, biconvex tablets debossed
‘202’ on one side and
‘ARCOXIA 90’ on the other side.
120 mg Tablets: Pale-green, apple-shaped, biconvex tablets debossed
‘204’ on one side
and ‘ARCOXIA 120’ on the other side.
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
ARCOXIA tablets are indicated for:
−
Symptomatic relief of osteoarthritis (OA),
−
Rheumatoid arthritis (RA),
−
Symptomatic relief of ankylosing spondylitis (AS),
−
Pain and signs of inflammation associated with acute gouty arthritis,
−
Treatment of acute pain, including that related to primary
dysmenorrhea and minor
dental procedures.
The decision to prescribe a selective COX-2 inhibitor should be based
on an assessment
of
the
individual
patient’s
overall
risks,
taking
into
consideration
other
available
therapeutic
options
(see
4.3 ‘Contra-indications’
and
4.4 ‘Special
warnings
and
precautions for use’).
4.2
Posology and method of administration
ARCOXIA is administered orally and may be taken with or without food.
The onset of
drug effect may be faster when ARCOXIA is administered without food.
This should be
considered when rapid symptomatic relief is needed. ARCOXIA should be
administered
for the shortest duration possible and the lowest effective daily dose
should be used.
Osteoarthritis
The recommended dose is 30 mg once daily. In some patients with
insufficien
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索

ドキュメントの履歴を表示する